Radiologist Zerhouni exits as director of NIH

  
Dr. Elias A Zerhouni, exiting director of the NIH. Image Source: www.genome.gov 
Elias A. Zerhouni, MD, the director of the National Institutes of Health (NIH) and a former executive at Johns Hopkins School of Medicine in Baltimore, will step down at the end of October.

Zerhouni, who gave the New Horizons lecture at last year’s meeting of the Radiological Society of North America (RSNA), said he will “pursue writing projects and explore other professional opportunities.”

The NIH reported that a replacement has not been named.

Modern Healthcare reported that his decision to leave was based on the conclusion of his tenure. He said the decision to leave prior to the elections signaled that he was not interested in continuing in his role as NIH director. In addition, “I wanted to allow people [within the NIH] to prepare for the transition” sooner rather than later, following the elections and the establishment of a new administration, he explained.

He also said that his departure had no direct connection to a probe requested by Sen. Chuck Grassley, R-Iowa, who called for an investigation into whether government health officials violated a policy meant to stem conflicts of interest at the NIH. The probe was sought by Grassley, the Senate Finance Committee’s ranking member, after a medical adviser was found to have retained ties to both an academic medical center and a cardiac device vendor, Modern Healthcare reported.

At the Bethesda, Md.-based NIH, Zerhouni oversaw the agency’s 27 institutes that employ more than 18,000 people and have a combined budget of $29.5 billion. The NIH supports more than 325,000 researcher personnel at more than 3,100 institutions throughout the U.S. and globally.

He spearheaded the launch of several biotech research initiatives and headed a number of NIH Roadmap efforts, a series of strategic plans to guide medical research. He also worked to lower barriers between disciplines of science and encourage trans-NIH collaborations, the agency said.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.